Literature DB >> 24999468

Commentary on "data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry".

Mohammad Mohammadianpanah1.   

Abstract

Entities:  

Year:  2014        PMID: 24999468      PMCID: PMC4079815          DOI: 10.3393/ac.2014.30.3.151

Source DB:  PubMed          Journal:  Ann Coloproctol        ISSN: 2287-9714


× No keyword cloud information.
To the editor In the July 2013 issue of Annals of Coloproctology, I read with great interest the article entitled "Data on the Characteristics and the Survival of Korean Patients with Colorectal Cancer from the Korea Central Cancer Registry" by Park et al. [1]. That study is one of the largest reports on colorectal cancer published in the literature. It provides valuable information regarding the characteristics and oncologic outcomes of Korean patients with colorectal cancer. However, in the discussion section, there was a paucity of comparisons of the characteristics and the survival of Korean patients suffering from colorectal cancer with those of European and American colorectal colorectal-cancer patients. In Korean patients, the rectum accounts for a higher proportion of colorectal-cancer primary sites compared to European and American patients [1, 2]. A similar distribution is also seen in the Iranian population [3]. Table 1 illustrates the distributions of primary tumor sites of colorectal cancer in Korea, Europe, and the United States (US). Moreover, the Korean patients showed a lower proportion for localized disease and a higher proportion for regional stage compared to European and American patients [1, 4] (Table 1). We also found a similar finding among Iranian patients with colorectal cancer [3, 5]. In the study by Park et al. [1], the 5-year survival of Korean patients with colorectal cancer was 72.1%, which is significantly higher than the 5-year survival rates in European countries (43%) and the US (62%) [1, 2, 6, 7]. Therefore, a discrepancy is seen to exist between this higher 5-year survival rate and the higher proportion of stage III cancers in Korea compared to the West.
Table 1

Clinicopathological features and overall survivals of Korean, European, and American patients with colorectal cancer [1, 4]

Rt., right; Lt., left.

  5 in total

1.  Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery.

Authors:  L Ciccolallo; R Capocaccia; M P Coleman; F Berrino; J W W Coebergh; R A M Damhuis; J Faivre; C Martinez-Garcia; H Møller; M Ponz de Leon; G Launoy; N Raverdy; E M I Williams; G Gatta
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

2.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

3.  Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology.

Authors:  G Gatta; L Ciccolallo; R Capocaccia; M P Coleman; T Hakulinen; H Møller; F Berrino
Journal:  Eur J Cancer       Date:  2003-10       Impact factor: 9.162

4.  Investigation of clinical manifestations in korean colorectal cancer patients.

Authors:  Hye Young Koo; Kyu Joo Park; Jae Hwan Oh; Sung Bum Kang; Seong Taek Oh; Woo Yong Lee
Journal:  Ann Coloproctol       Date:  2013-08-29

5.  Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry.

Authors:  Hyoung-Chul Park; Aesun Shin; Byung-Woo Kim; Kyu-Won Jung; Young-Joo Won; Jae Hwan Oh; Seung-Yong Jeong; Chang Sik Yu; Bong Hwa Lee
Journal:  Ann Coloproctol       Date:  2013-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.